Middle East & Africa Prostate Cancer Nuclear Medicine Market Forecast to 2028 – COVID-19 Impact and Regional Analysis – by Type (PET and SPECT), PET Product (F-18, C-11, and Ga68-PSMA), and End User (Hospitals, Clinics, and Others)
The MEA prostate cancer nuclear medicine market is expected to grow from US$ 35.66 million in 2022 to US$ 62.49 million by 2028; it is estimated to grow at a CAGR of 9.8% from 2022 to 2028.
Prostate cancer is a prevalent male malignancy that remains a major health issue. In the clinical care of patients, imaging is critical. Prostate cancer imaging provides precise disease characterization through synthesizing anatomic, functional, and molecular imaging information. Prostate cancer detection has increased due to advances in imaging technologies, such as magnetic resonance imaging (MRI) and positron emission tomography (PET)/computed tomography (CT). Lesion detection and local staging have improved due to MRI. Diffusion-weighted MRI, MR spectroscopy, and dynamic contrast-enhanced MRI are among the MRI techniques used to assess function. Conventional imaging options, such as computed tomography (CT), magnetic resonance imaging (MRI), and ultrasound, are used for prostate cancer patients to detect organ-confined or metastatic disease for staging and prognosis. However, the use of imaging for assessing tumor grade, staging, finding minimal metastatic disease, and separating fatal from a nonlethal disease needs to be improved. Hybrid imaging approaches for diagnosis use complementary structural and morphological data to improve imaging resolution and sensitivity. For instance, the FDA approved a complementary diagnostic imaging agent, Locametz, after radiolabeling with gallium-68 to identify PSMA-positive lesions. After radiolabeling, this imaging agent may be used to identify PSMA-positive lesions in adult patients with mCRPC through a positron emission tomography scan.
With the new features and technologies, vendors can attract new customers and expand their footprints in emerging markets. This factor is likely to drive the MEA prostate cancer nuclear medicine market. The MEA prostate cancer nuclear medicine market is expected to grow at a good CAGR during the forecast period.
MEA Prostate cancer nuclear medicine Market Revenue and Forecast to 2028 (US$ Million)
MEA Prostate cancer nuclear medicine Market Segmentation
The MEA prostate cancer nuclear medicine market is segmented into type, PET product, end user, and country. Based on type, the MEA prostate cancer nuclear medicine market is divided into PET and SPECT. The PET dominated the MEA prostate cancer nuclear medicine market in 2022. Based on PET product, the MEA prostate cancer nuclear medicine market is categorized into F-18, C-11, and Ga68-PSMA. The F-18 segment dominated the MEA prostate cancer nuclear medicine market in 2022. Based on end user, the MEA prostate cancer nuclear medicine market is categorized into hospitals, clinics, and others. The hospitals segment dominated the MEA prostate cancer nuclear medicine market in 2022. Based on country, the MEA prostate cancer nuclear medicine market is segmented into Saudi Arabia, UAE, South Africa, and the rest of the MEA. The Saudi Arabia segment dominated the MEA prostate cancer nuclear medicine market in 2022.
ImaginAb; Curium; ABX advanced biochemical compounds GmbH; Telix Pharmaceuticals Ltd; Novartis AG; and Lantheus Medical Imaging, Inc. by Altair are among the leading companies in the MEA prostate cancer nuclear medicine market.
1. Introduction
1.1 Scope of the Study
1.2 The Insight Partners Research Report Guidance
1.3 Market Segmentation
1.3.1 MEA Prostate Cancer Nuclear Medicine Diagnostics Market – By Type
1.3.2 MEA Prostate Cancer Nuclear Medicine Diagnostics Market – By PET Product
1.3.3 MEA Prostate Cancer Nuclear Medicine Diagnostics Market – By End User
1.3.4 MEA Prostate Cancer Nuclear Medicine Diagnostics Market – By Country
2. Key Takeaways
3. Research Methodology
3.1 Coverage
3.2 Secondary Research
3.3 Primary Research
4. MEA Prostate Cancer Nuclear Medicine Diagnostics Market – Market Landscape
4.1 Overview
4.2 PEST Analysis
4.2.1 MEA PEST Analysis
4.3 Experts Opinion
5. MEA Prostate Cancer Nuclear Medicine Diagnostics Market– Key Market Dynamics
5.1 Market Drivers
5.1.1 Surging Prevalence of Prostate Cancer
5.1.2 Soaring Demand for Early and Precise Diagnosis of Prostate Cancer
5.2 Market Restraints
5.2.1 Overpriced Related to the Prostate Cancer Diagnostics and Treatment
5.3 Market Opportunities
5.3.1 Expanding Use of Radiopharmaceuticals in Prostate Cancer
5.4 Future Trends
5.4.1 Developing Research Activities for Development of Innovative Imaging Agents
5.5 Impact Analysis
6. Prostate Cancer Nuclear Medicine Diagnostics Market– MEA Analysis
6.1 MEA Prostate Cancer Nuclear Medicine Diagnostics Market Revenue Forecast and Analysis
7. MEA Prostate Cancer Nuclear Medicine Diagnostics Market Analysis – By Type
7.1 Overview
7.2 MEA Prostate Cancer Nuclear Medicine Diagnostics Market, By Type, 2022 & 2028 (%)
7.3 SPECT
7.3.1 Overview
7.3.2 SPECT: Prostate Cancer Nuclear Medicine Diagnostics Market Revenue and Forecasts to 2028 (US$ Million)
7.4 PET
7.4.1 Overview
7.4.2 PET: Prostate Cancer Nuclear Medicine Diagnostics Market Revenue and Forecasts to 2028 (US$ Million)
8. MEA Prostate Cancer Nuclear Medicine Diagnostics Market Analysis – By PET Product
8.1 Overview
8.2 MEA Prostate Cancer Nuclear Medicine Diagnostics Market, By PET Product, 2022 & 2028 (%)
8.3 F-18
8.3.1 Overview
8.3.2 F-18: Prostate Cancer Nuclear Medicine Diagnostics Market Revenue and Forecast to 2028 (US$ Million)
8.4 C-11
8.4.1 Overview
8.4.2 C-11: Prostate Cancer Nuclear Medicine Diagnostics Market Revenue and Forecast to 2028 (US$ Million)
8.5 GA 68 PSMA
8.5.1 Overview
8.5.2 GA 68 PSMA: Prostate Cancer Nuclear Medicine Diagnostics Market Revenue and Forecast to 2028 (US$ Million)
9. MEA Prostate Cancer Nuclear Medicine Diagnostics Market – By End User
9.1 Overview
9.2 MEA Prostate Cancer Nuclear Medicine Diagnostics Market Share by End User- 2022 & 2028 (%)
9.3 Hospitals
9.3.1 Overview
9.3.2 Hospitals: Prostate Cancer Nuclear Medicine Diagnostics Market Revenue and Forecast to 2028 (US$ Million)
9.4 Clinics
9.4.1 Overview
9.4.2 Clinics: Prostate Cancer Nuclear Medicine Diagnostics Market Revenue and Forecast to 2028 (US$ Million)
9.5 Others
9.5.1 Overview
9.5.2 Others: Prostate Cancer Nuclear Medicine Diagnostics Market Revenue and Forecast to 2028 (US$ Million)
10. MEA Prostate Cancer Nuclear Medicine Diagnostics Market – By Country Analysis
10.1 MEA Prostate Cancer Nuclear Medicine Diagnostics Market Revenue and Forecasts To 2028
10.1.1 Overview
10.1.2 MEA: Prostate Cancer Nuclear Medicine Diagnostics Market, by Country, 2021 & 2028 (%)
10.1.2.1 UAE: Prostate Cancer Nuclear Medicine Diagnostics Market – Revenue and Forecast to 2028 (US$ ‘Million)
10.1.2.1.1 Overview
10.1.2.1.2 UAE: Prostate Cancer Nuclear Medicine Diagnostics Market – Revenue and Forecast to 2028 (US$ ‘Million)
10.1.2.1.3 UAE: Prostate Cancer Nuclear Medicine Diagnostics Market, by Type, 2019–2028 (US$ ‘Million)
10.1.2.1.4 UAE: Prostate Cancer Nuclear Medicine Diagnostics Market, PET Product, 2019–2028 (US$ ‘Million)
10.1.2.1.5 UAE: Prostate Cancer Nuclear Medicine Diagnostics Market, by End User, 2019–2028 (US$ ‘Million)
10.1.2.2 Saudi Arabia: Prostate Cancer Nuclear Medicine Diagnostics Market – Revenue and Forecast to 2028 (US$ ‘Million)
10.1.2.2.1 Overview
10.1.2.2.2 Saudi Arabia: Prostate Cancer Nuclear Medicine Diagnostics Market – Revenue and Forecast to 2028 (US$ ‘Million)
10.1.2.2.3 Saudi Arabia: Prostate Cancer Nuclear Medicine Diagnostics Market, by Type, 2019–2028 (US$ ‘Million)
10.1.2.2.4 Saudi Arabia: Prostate Cancer Nuclear Medicine Diagnostics Market, PET Product, 2019–2028 (US$ ‘Million)
10.1.2.2.5 Saudi Arabia: Prostate Cancer Nuclear Medicine Diagnostics Market, by End User, 2019–2028 (US$ ‘Million)
10.1.2.3 South Africa: Prostate Cancer Nuclear Medicine Diagnostics Market – Revenue and Forecast to 2028 (US$ ‘Million)
10.1.2.3.1 Overview
10.1.2.3.2 South Africa: Prostate Cancer Nuclear Medicine Diagnostics Market – Revenue and Forecast to 2028 (US$ ‘Million)
10.1.2.3.3 South Africa: Prostate Cancer Nuclear Medicine Diagnostics Market, by Type, 2019–2028 (US$ ‘Million)
10.1.2.3.4 South Africa: Prostate Cancer Nuclear Medicine Diagnostics Market, PET Product, 2019–2028 (US$ ‘Million)
10.1.2.3.5 South Africa: Prostate Cancer Nuclear Medicine Diagnostics Market, by End User, 2019–2028 (US$ ‘Million)
10.1.2.4 Rest of MEA: Prostate Cancer Nuclear Medicine Diagnostics Market – Revenue and Forecast to 2028 (US$ ‘Million)
10.1.2.4.1 Overview
10.1.2.4.2 Rest of MEA: Prostate Cancer Nuclear Medicine Diagnostics Market – Revenue and Forecast to 2028 (US$ ‘Million)
10.1.2.4.3 Rest of MEA: Prostate Cancer Nuclear Medicine Diagnostics Market, by Type, 2019–2028 (US$ ‘Million)
10.1.2.4.4 Rest of MEA: Prostate Cancer Nuclear Medicine Diagnostics Market, PET Product, 2019–2028 (US$ ‘Million)
10.1.2.4.5 Rest of MEA: Prostate Cancer Nuclear Medicine Diagnostics Market, by End User, 2019–2028 (US$ ‘Million)
11. Prostate Cancer Nuclear Medicine Diagnostics Market–Industry Landscape
11.1 Overview
11.2 Growth Strategies in the Prostate Cancer Nuclear Medicine Diagnostics Market, 2021-2028
11.3 Inorganic Growth Strategies
11.3.1 Overview
11.4 Organic Growth Strategies
11.4.1 Overview
12. Company Profiles
12.1 ImaginAb
12.1.1 Key Facts
12.1.2 Business Description
12.1.3 Products and Services
12.1.4 Financial Overview
12.1.5 SWOT Analysis
12.1.6 Key Developments
12.2 Curium
12.2.1 Key Facts
12.2.2 Business Description
12.2.3 Products and Services
12.2.4 Financial Overview
12.2.5 SWOT Analysis
12.2.6 Key Developments
12.3 ABX advanced biochemical compounds GmbH
12.3.1 Key Facts
12.3.2 Business Description
12.3.3 Products and Services
12.3.4 Financial Overview
12.3.5 SWOT Analysis
12.3.6 Key Developments
12.4 Telix Pharmaceuticals Ltd.
12.4.1 Key Facts
12.4.2 Business Description
12.4.3 Products and Services
12.4.4 Financial Overview
12.4.5 SWOT Analysis
12.4.6 Key Developments
12.5 Novartis AG
12.5.1 Key Facts
12.5.2 Business Description
12.5.3 Products and Services
12.5.4 Financial Overview
12.5.5 SWOT Analysis
12.5.6 Key Developments
12.6 Lantheus Medical Imaging, Inc.
12.6.1 Key Facts
12.6.2 Business Description
12.6.3 Products and Services
12.6.4 Financial Overview
12.6.5 SWOT Analysis
12.6.6 Key Developments
13. Appendix
13.1 About The Insight Partners
13.2 Glossary of Terms
LIST OF TABLES
Table 1. UAE: Prostate Cancer Nuclear Medicine Diagnostics Market, by Type – Revenue and Forecast to 2028 (US$ ‘Million)
Table 2. UAE: Prostate Cancer Nuclear Medicine Diagnostics Market, PET Product – Revenue and Forecast to 2028 (US$ ‘Million)
Table 3. UAE: Prostate Cancer Nuclear Medicine Diagnostics Market, by End User – Revenue and Forecast to 2028 (US$ ‘Million)
Table 4. Saudi Arabia: Prostate Cancer Nuclear Medicine Diagnostics Market, by Type – Revenue and Forecast to 2028 (US$ ‘Million)
Table 5. Saudi Arabia: Prostate Cancer Nuclear Medicine Diagnostics Market, PET Product – Revenue and Forecast to 2028 (US$ ‘Million)
Table 6. Saudi Arabia: Prostate Cancer Nuclear Medicine Diagnostics Market, by End User – Revenue and Forecast to 2028 (US$ ‘Million)
Table 7. South Africa: Prostate Cancer Nuclear Medicine Diagnostics Market, by Type – Revenue and Forecast to 2028 (US$ ‘Million)
Table 8. South Africa: Prostate Cancer Nuclear Medicine Diagnostics Market, PET Product – Revenue and Forecast to 2028 (US$ ‘Million)
Table 9. South Africa: Prostate Cancer Nuclear Medicine Diagnostics Market, by End User – Revenue and Forecast to 2028 (US$ ‘Million)
Table 10. Rest of Middle East and Africa: Prostate Cancer Nuclear Medicine Diagnostics Market, by Type – Revenue and Forecast to 2028 (US$ ‘Million)
Table 11. Rest of MEA: Prostate Cancer Nuclear Medicine Diagnostics Market, PET Product – Revenue and Forecast to 2028 (US$ ‘Million)
Table 12. Rest of Middle East and Africa: Prostate Cancer Nuclear Medicine Diagnostics Market, by End User – Revenue and Forecast to 2028 (US$ ‘Million)
Table 13. Recent Inorganic Growth Strategies in the Prostate Cancer Nuclear Medicine Diagnostics Market
Table 14. Recent Organic Growth Strategies in the Prostate Cancer Nuclear Medicine Diagnostics Market
Table 15. Glossary of Terms, Prostate Cancer Nuclear Medicine Diagnostics Market
LIST OF FIGURES
Figure 1. MEA Prostate Cancer Nuclear Medicine Diagnostics Market Segmentation
Figure 2. MEA Prostate Cancer Nuclear Medicine Diagnostics Market, By Country
Figure 3. MEA Prostate Cancer Nuclear Medicine Diagnostics Market Overview
Figure 4. PET Segment Held Largest Share of Type Segment in Prostate Cancer Nuclear Medicine Diagnostics Market
Figure 5. MEA is Expected to Show Remarkable Growth During the Forecast Period
Figure 6. MEA: PEST Analysis
Figure 7. MEA Experts Opinion
Figure 8. MEA Prostate Cancer Nuclear Medicine Diagnostics Market Impact Analysis of Drivers and Restraints
Figure 9. MEA Prostate Cancer Nuclear Medicine Diagnostics Market– Revenue Forecast and Analysis – 2020 - 2028
Figure 10. MEA Prostate Cancer Nuclear Medicine Diagnostics Market, by Type, 2022 & 2028 (%)
Figure 11. MEA SPECT: Prostate Cancer Nuclear Medicine Diagnostics Market Revenue and Forecasts to 2028 (US$ Million)
Figure 12. MEA PET: Prostate Cancer Nuclear Medicine Diagnostics Market Revenue and Forecasts to 2028 (US$ Million)
Figure 13. MEA Prostate Cancer Nuclear Medicine Diagnostics Market, by PET Product, 2022 & 2028 (%)
Figure 14. MEA F-18: Prostate Cancer Nuclear Medicine Diagnostics Market Revenue and Forecasts To 2028 (US$ Million)
Figure 15. MEA C-11: Prostate Cancer Nuclear Medicine Diagnostics Market Revenue and Forecasts To 2028 (US$ Million)
Figure 16. MEA GA 68 PSMA: Prostate Cancer Nuclear Medicine Diagnostics Market Revenue and Forecasts To 2028 (US$ Million)
Figure 17. MEA Prostate Cancer Nuclear Medicine Diagnostics Market Share by End User - 2022 & 2028 (%)
Figure 18. MEA Hospitals: Prostate Cancer Nuclear Medicine Diagnostics Market Revenue and Forecasts To 2028 (US$ Million)
Figure 19. MEA Clinics: Prostate Cancer Nuclear Medicine Diagnostics Market Revenue and Forecasts To 2028 (US$ Million)
Figure 20. MEA Others: Prostate Cancer Nuclear Medicine Diagnostics Market Revenue and Forecasts To 2028 (US$ Million)
Figure 21. Middle East and Africa: Prostate Cancer Nuclear Medicine Diagnostics Market, by Key Country – Revenue (2022) (US$ ‘Million)
Figure 22. MEA: Prostate Cancer Nuclear Medicine Diagnostics Market, by Country, 2022 & 2028 (%)
Figure 23. UAE: Prostate Cancer Nuclear Medicine Diagnostics Market – Revenue and Forecast to 2028 (US$ ‘Million)
Figure 24. Saudi Arabia: Prostate Cancer Nuclear Medicine Diagnostics Market – Revenue and Forecast to 2028 (US$ ‘Million)
Figure 25. South Africa: Prostate Cancer Nuclear Medicine Diagnostics Market – Revenue and Forecast to 2028 (US$ ‘Million)
Figure 26. Rest of MEA: Prostate Cancer Nuclear Medicine Diagnostics Market – Revenue and Forecast to 2028 (US$ ‘Million)
Figure 27. Growth Strategies in the Prostate Cancer Nuclear Medicine Diagnostics Market, 2021-2028
- ImaginAb
- Curium
- ABX advanced biochemical compounds GmbH
- Telix Pharmaceuticals Ltd
- Novartis AG
- Lantheus Medical Imaging, Inc.
- Save and reduce time carrying out entry-level research by identifying the growth, size, leading players, and segments in the MEA prostate cancer nuclear medicine market.
- Highlights key business priorities in order to assist companies to realign their business strategies
- The key findings and recommendations highlight crucial progressive industry trends in the MEA prostate cancer nuclear medicine market, thereby allowing players across the value chain to develop effective long-term strategies
- Develop/modify business expansion plans by using substantial growth offering developed and emerging markets
- Scrutinize in-depth MEA market trends and outlook coupled with the factors driving the MEA prostate cancer nuclear medicine market, as well as those hindering it
- Enhance the decision-making process by understanding the strategies that underpin commercial interest with respect to client products, segmentation, pricing, and distribution